The use of pergonal for the induction of ovulation.
With proper patient selection, appropriate pretreatment studies and careful monitoring will ensure that patients ovulate safely. Table 7 is a summary of the results that may be expected following properly monitored hMG therapy. Among estrogen-deficient patients without other causes of infertility, the cumulative pregnancy rate after six cycles will exceed 90%. However, among normoestrogenic patients with no other infertility factors the cumulative conception rate has been reported to be only 50% after 12 courses of therapy, although with the use of ultrasound monitoring it is likely that this latter figure will improve. Nevertheless, these data may be used to afford couples with a realistic prognosis.
D000014:Abnormalities, Drug-Induced / Q000209:etiology; D000858:Anovulation / Q000188:drug therapy; D006063:Chorionic Gonadotropin / Q000627:therapeutic use; D002996:Clomiphene / Q000627:therapeutic use; D003907:Dexamethasone / Q000627:therapeutic use; D004958:Estradiol / Q000097:blood; D004967:Estrogens / Q000627:therapeutic use; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D007231:Infant, Newborn; D008525:Medroxyprogesterone / Q000627:therapeutic use; D008596:Menotropins / Q000009:adverse effects / Q000627:therapeutic use*; D008599:Menstruation Disturbances / Q000188:drug therapy; D006080:Ovarian Follicle / Q000254:growth & development; D010062:Ovulation Induction / Q000379:methods*; D011247:Pregnancy; D011374:Progesterone; D014463:Ultrasonography
D006063:Chorionic Gonadotropin; D004967:Estrogens; D002996:Clomiphene; D011374:Progesterone; D004958:Estradiol; D008596:Menotropins; D003907:Dexamethasone; D005640:Follicle Stimulating Hormone; D008525:Medroxyprogesterone